Olivia Gardner

Phase II Study of the MEK1/MEK2 Inhibitor Trametinib in Patients With Metastatic <i>BRAF</i> -Mutant Cutaneous Melanoma Previously Treated With or Without a BRAF Inhibitor

Kevin B. Kim, Richard Kefford, Anna C. Pavlick et al. · Journal of Clinical Oncology · 2012 · 477 citations · Full text

Medicine, Oncology, Pharmacology +17

Dependence of Peroxisome Proliferator-activated Receptor Ligand-induced Mitogen-activated Protein Kinase Signaling on Epidermal Growth Factor Receptor Transactivation

Olivia Gardner, Brian J. Dewar, H. Shelton Earp et al. · Journal of Biological Chemistry · 2003 · 106 citations · Full text

Life Sciences, Biochemistry, Molecular Biology +8

Peroxisome Proliferator-activated Receptor γ-independent Activation of p38 MAPK by Thiazolidinediones Involves Calcium/Calmodulin-dependent Protein Kinase II and Protein Kinase R

Olivia Gardner, Chung-Wai Shiau, Ching-Shih Chen et al. · Journal of Biological Chemistry · 2005 · 90 citations · Full text

Medicine, Endocrinology, Pharmacology +14

Population pharmacokinetics and exposure–response of trametinib, a MEK inhibitor, in patients with BRAF V600 mutation-positive melanoma

Danièle Ouellet, Nastya Kassir, Joannellyn Chiu et al. · Cancer Chemotherapy and Pharmacology · 2016 · 57 citations

Medicine, Oncology, Pharmacokinetics +17

Chemoimmunotherapy Using Pegylated Liposomal Doxorubicin and Interleukin-18 in Recurrent Ovarian Cancer: A Phase I Dose-Escalation Study

Fiona Simpkins, Aurea E. Flores, Christina Chu et al. · Cancer Immunology Research · 2013 · 53 citations · Full text

Medicine, Oncology, Pharmacology +17